サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1223397

欧州の脳腫瘍診断市場：産業動向・予測 (～2030年)

Europe Brain Cancer Diagnostic Market - Industry Trends and Forecast to 2030
出版日: | 発行: Data Bridge Market Research | ページ情報: 英文 166 Pages | 納期: お問合せ

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
欧州の脳腫瘍診断市場：産業動向・予測 (～2030年)
出版日: 2023年01月01日
発行: Data Bridge Market Research
ページ情報: 英文 166 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の脳腫瘍診断の市場規模は、2023年から2030年の予測期間中に18.2 %のCAGRで成長すると予測されています。

世界の脳腫瘍患者数の増加、脳腫瘍の早期診断に対する意識の高まり、脳腫瘍細胞へのドラッグデリバリー技術の革新などの要因が同市場の成長を推進しています。

当レポートでは、欧州の脳腫瘍診断の市場を調査し、市場概要、市場成長への各種影響因子の分析、法規制シナリオ、市場規模の推移・予測、各種区分・主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 欧州の脳腫瘍診断市場：分類

第3章 エグゼクティブサマリー

第4章 重要考察

  • PESTEL分析
  • ポーターの分析

第5章 疫学

第6章 欧州の脳腫瘍診断市場：産業考察

第7章 欧州の脳腫瘍診断市場：法規制

第8章 市場概要

  • 促進要因
  • 抑制要因
  • 機会
  • 課題

第9章 欧州の脳腫瘍診断市場：検査タイプ別

  • 概要
  • 画像検査
    • CTスキャン
    • MRI
    • PET
    • その他
  • 分子検査
  • 脳波検査（EEG）
  • 腰椎穿刺
  • 生検
    • オープン生検
    • 定位生検
    • 針生検
    • 神経内視鏡検査
  • その他

第10章 欧州の脳腫瘍診断市場：腫瘍タイプ別

  • 概要
  • 多形性膠芽細胞腫
  • 髄膜腫
  • 星細胞系腫瘍
  • 聴神経腫瘍
  • 乏突起神経膠腫
  • その他

第11章 欧州の脳腫瘍診断市場：年齢層別

  • 概要
  • 35-65歳
  • 65歳以上
  • 21歳未満
  • 21-34歳

第12章 欧州の脳腫瘍診断市場：エンドユーザー別

  • 概要
  • 病院
  • 専門クリニック
  • 診断センター・研究機関
  • 外来手術センター
  • その他

第13章 欧州の脳腫瘍診断市場：地域別

  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • スイス
    • オランダ
    • トルコ
    • ベルギー
    • その他

第14章 欧州の脳腫瘍診断市場：企業情勢

  • 企業シェア分析：欧州

第15章 SWOT分析

第16章 欧州の脳腫瘍診断市場：企業プロファイル

  • KONINKLIJKE PHILIPS N.V.
  • CANON INC.
  • SIEMENS HEALTHCARE GMBH
  • BD
  • NIHON KOHDEN CORPORATION.
  • BIOCEPT, INC.
  • BIOMIND
  • CEREBRAL DIAGNOSTIC
  • DXCOVER LIMITED
  • FONAR CORP.
  • FUJIFILM CORPORATION
  • GE HEALTHCARE.
  • HITACHI, LTD.
  • MINFOUND MEDICAL SYSTEMS CO.,
  • NANTOMICS.
  • NEUSOFT CORPORATION
  • SEQUOIA HEALTHCARE.
  • STERNMED GMBH
  • THERMO FISHER SCIENTIFIC INC.
  • TIME MEDICAL HOLDING

第17章 質問事項

第18章 関連レポート

図表

LIST OF TABLES

  • TABLE 1 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 56
  • TABLE 2 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 57
  • TABLE 3 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 58
  • TABLE 4 EUROPE MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 59
  • TABLE 5 EUROPE ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 60
  • TABLE 6 EUROPE LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 60
  • TABLE 7 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 61
  • TABLE 8 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 61
  • TABLE 9 EUROPE OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 62
  • TABLE 10 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 66
  • TABLE 11 EUROPE GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 67
  • TABLE 12 EUROPE MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 68
  • TABLE 13 EUROPE ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 69
  • TABLE 14 EUROPE ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 70
  • TABLE 15 EUROPE OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 71
  • TABLE 16 EUROPE OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 72
  • TABLE 17 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 76
  • TABLE 18 EUROPE 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 77
  • TABLE 19 EUROPE 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 78
  • TABLE 20 EUROPE BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 79
  • TABLE 21 EUROPE 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 80
  • TABLE 22 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 84
  • TABLE 23 EUROPE HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 85
  • TABLE 24 EUROPE SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 86
  • TABLE 25 EUROPE DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 87
  • TABLE 26 EUROPE AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 88
  • TABLE 27 EUROPE OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 89
  • TABLE 28 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 95
  • TABLE 29 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 95
  • TABLE 30 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 96
  • TABLE 31 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 96
  • TABLE 32 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 96
  • TABLE 33 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 97
  • TABLE 34 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 97
  • TABLE 35 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 36 GERMANY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 37 GERMANY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 38 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 99
  • TABLE 39 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 99
  • TABLE 40 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 99
  • TABLE 41 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
  • TABLE 42 FRANCE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
  • TABLE 43 FRANCE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
  • TABLE 44 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 101
  • TABLE 45 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 101
  • TABLE 46 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 101
  • TABLE 47 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 48 U.K. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 49 U.K. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 50 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 51 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 103
  • TABLE 52 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 103
  • TABLE 53 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 54 ITALY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 55 ITALY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 56 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 57 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 105
  • TABLE 58 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 105
  • TABLE 59 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 60 SPAIN IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 61 SPAIN BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 62 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 63 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 107
  • TABLE 64 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 107
  • TABLE 65 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 66 RUSSIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 67 RUSSIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 68 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 69 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 109
  • TABLE 70 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 109
  • TABLE 71 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 72 SWITZERLAND IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 73 SWITZERLAND BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 74 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 75 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 111
  • TABLE 76 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 111
  • TABLE 77 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 112
  • TABLE 78 NETHERLANDS IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 112
  • TABLE 79 NETHERLANDS BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 112
  • TABLE 80 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 113
  • TABLE 81 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 113
  • TABLE 82 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 113
  • TABLE 83 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 84 TURKEY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 85 TURKEY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 86 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 87 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 115
  • TABLE 88 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 115
  • TABLE 89 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 90 BELGIUM IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 91 BELGIUM BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 92 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 93 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 117
  • TABLE 94 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 117
  • TABLE 95 REST OF EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 118

LIST OF FIGURES

  • FIGURE 1 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 21
  • FIGURE 2 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 24
  • FIGURE 3 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 25
  • FIGURE 4 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 26
  • FIGURE 5 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 26
  • FIGURE 6 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 27
  • FIGURE 7 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID 29
  • FIGURE 8 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 31
  • FIGURE 9 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID 32
  • FIGURE 10 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 35
  • FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 36
  • FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 36
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET 45
  • FIGURE 14 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022 53
  • FIGURE 15 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION) 54
  • FIGURE 16 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030) 54
  • FIGURE 17 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE 55
  • FIGURE 18 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022 63
  • FIGURE 19 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION) 64
  • FIGURE 20 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030) 64
  • FIGURE 21 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE 65
  • FIGURE 22 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022 73
  • FIGURE 23 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 74
  • FIGURE 24 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030) 74
  • FIGURE 25 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE 75
  • FIGURE 26 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022 81
  • FIGURE 27 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION) 82
  • FIGURE 28 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030) 82
  • FIGURE 29 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 83
  • FIGURE 30 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022) 91
  • FIGURE 31 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022) 92
  • FIGURE 32 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030) 92
  • FIGURE 33 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030) 93
  • FIGURE 34 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030) 93
  • FIGURE 35 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%) 118
目次

Europe brain cancer diagnostic market is projected to register a substantial CAGR of 18.2 % in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Europe Brain Cancer Diagnostic Market, By Test Type (Imaging Test, Biopsy, Lumber Puncture, Molecular Testing, Electroencephalography (EEG), and Others), Cancer Type (Acoustic Neuroma, Astrocytomas, Glioblastoma Multiforme, Meningiomas, Oligodendroglioma, and Others), Age Group (Below 21,21-34, 35-65, and 65 and Above), End User (Hospitals, Specialty Clinics, Diagnostic Centers & Research Institutes, Ambulatory Surgical Centers, and Others), Country (Russia, Spain, Turkey, Germany, Italy, United Kingdom, France, Belgium, Switzerland, Netherlands, and the Rest of Europe), Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe brain cancer diagnostic market are:

Rising cases of brain cancer worldwide

Rising awareness of early diagnosis of brain cancer

Improved imaging techniques

Innovations in drug delivery to brain cancer cells

Market Players

Some of the key market players for the Europe brain cancer diagnostic market are listed below:

NIHON KOHDEN CORPORATION.

FUJIFILM Holdings Corporation

GE HealthCare

Koninklijke Philips N.V.

BD

Siemens Healthcare GmbH

Canon Inc.

Others

TABLE OF CONTENTS

1 INTRODUCTION 24

  • 1.1 OBJECTIVES OF THE STUDY 24
  • 1.2 MARKET DEFINITION 24
  • 1.3 OVERVIEW OF THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET 24
  • 1.4 CURRENCY AND PRICING 26
  • 1.5 LIMITATIONS 26
  • 1.6 MARKETS COVERED 26

2 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 29

  • 2.1 MARKETS COVERED 29
  • 2.2 GEOGRAPHICAL SCOPE 30
  • 2.3 YEARS CONSIDERED FOR THE STUDY 31
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 32
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
  • 2.6 MULTIVARIATE MODELLING 36
  • 2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 36
  • 2.8 DBMR MARKET POSITION GRID 37
  • 2.9 VENDOR SHARE ANALYSIS 39
  • 2.10 MARKET END USER COVERAGE GRID 40
  • 2.11 SECONDARY SOURCES 41

3 EXECUTIVE SUMMARY 42

4 PREMIUM INSIGHTS 44

  • 4.1 PESTEL ANALYSIS 45
  • 4.2 PORTER'S FIVE FORCES 46

5 EPIDEMIOLOGY 47

6 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT 48

7 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS 49

  • 7.1 REGULATORY SCENARIO IN THE U.S 49
  • 7.2 REGULATORY SCENARIO IN AUSTRALIA 50
  • 7.3 REGULATORY SCENARIO IN JAPAN 50
  • 7.4 REGULATORY SCENARIO IN CHINA 50

8 MARKET OVERVIEW 52

  • 8.1 DRIVERS 54
    • 8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE 54
    • 8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER 54
    • 8.1.3 IMPROVED IMAGING TECHNIQUES 55
    • 8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS 55
  • 8.2 RESTRAINTS 56
    • 8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER 56
    • 8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES 56
    • 8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS 57
  • 8.3 OPPORTUNITIES 57
    • 8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS 57
    • 8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC 57
    • 8.3.3 RISING HEALTHCARE EXPENDITURE 58
  • 8.4 CHALLENGES 59
    • 8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS 59
    • 8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 59

9 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE 60

  • 9.1 OVERVIEW 61
  • 9.2 IMAGING TEST 64
    • 9.2.1 CT SCAN 65
    • 9.2.2 MRI 65
    • 9.2.3 PET 65
    • 9.2.4 OTHERS 65
  • 9.3 MOLECULAR TESTING 66
  • 9.4 ELECTROENCEPHALOGRAPHY (EEG) 66
  • 9.5 LUMBAR PUNCTURE 67
  • 9.6 BIOPSY 68
    • 9.6.1 OPEN BIOPSY 69
    • 9.6.2 STEREOTACTIC BIOPSY 69
    • 9.6.3 NEEDLE BIOPSY 69
    • 9.6.4 NEUROENDOSCOPY 69
  • 9.7 OTHERS 69

10 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE 70

  • 10.1 OVERVIEW 71
  • 10.2 GLIOBLASTOMA MULTIFORME 74
  • 10.3 MENINGIOMAS 75
  • 10.4 ASTROCYTOMAS 76
  • 10.5 ACOUSTIC NEUROMA 77
  • 10.6 OLIGODENDROGLIOMA 78
  • 10.7 OLIGODENDROGLIOMA 78
  • 10.8 OTHERS 79

11 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP 80

  • 11.1 OVERVIEW 81
  • 11.2 35-65 84
  • 11.3 65 AND ABOVE 85
  • 11.4 BELOW 21 86
  • 11.5 21-34 87

12 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER 88

  • 12.1 OVERVIEW 89
  • 12.2 HOSPITALS 92
  • 12.3 SPECIALTY CLINICS 93
  • 12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES 94
  • 12.5 AMBULATORY SURGICAL CENTERS 95
  • 12.6 OTHERS 96

13 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY REGION 97

  • 13.1 EUROPE 98
    • 13.1.1 GERMANY 105
    • 13.1.2 FRANCE 107
    • 13.1.3 U.K. 109
    • 13.1.4 ITALY 111
    • 13.1.5 SPAIN 113
    • 13.1.6 RUSSIA 115
    • 13.1.7 SWITZERLAND 117
    • 13.1.8 NETHERLANDS 119
    • 13.1.9 TURKEY 121
    • 13.1.10 BELGIUM 123
    • 13.1.11 REST OF EUROPE 125

14 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE 126

  • 14.1 COMPANY SHARE ANALYSIS: EUROPE 126

15 SWOT ANALYSIS 127

16 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE 128

  • 16.1 KONINKLIJKE PHILIPS N.V. 128
    • 16.1.1 COMPANY SNAPSHOT 128
    • 16.1.2 REVENUE ANALYSIS 128
    • 16.1.3 COMPANY SHARE ANALYSIS 129
    • 16.1.4 PRODUCT PORTFOLIO 129
    • 16.1.5 RECENT DEVELOPMENTS 130
  • 16.2 CANON INC. 131
    • 16.2.1 COMPANY SNAPSHOT 131
    • 16.2.2 REVENUE ANALYSIS 131
    • 16.2.3 COMPANY SHARE ANALYSIS 132
    • 16.2.4 PRODUCT PORTFOLIO 132
    • 16.2.5 RECENT DEVELOPMENT 132
  • 16.3 SIEMENS HEALTHCARE GMBH 133
    • 16.3.1 COMPANY SNAPSHOT 133
    • 16.3.2 REVENUE ANALYSIS 134
    • 16.3.3 COMPANY SHARE ANALYSIS 134
    • 16.3.4 PRODUCT PORTFOLIO 135
    • 16.3.5 RECENT DEVELOPMENTS 135
  • 16.4 BD 136
    • 16.4.1 COMPANY SNAPSHOT 136
    • 16.4.2 REVENUE ANALYSIS 137
    • 16.4.3 COMPANY SHARE ANALYSIS 137
    • 16.4.4 PRODUCT PORTFOLIO 138
    • 16.4.5 RECENT DEVELOPMENTS 138
  • 16.5 NIHON KOHDEN CORPORATION. 139
    • 16.5.1 COMPANY SNAPSHOT 139
    • 16.5.2 RECENT FINANCIALS 139
    • 16.5.3 COMPANY SHARE ANALYSIS 140
    • 16.5.4 PRODUCT PORTFOLIO 140
    • 16.5.5 RECENT DEVELOPMENT 140
  • 16.6 BIOCEPT, INC. 141
    • 16.6.1 COMPANY SNAPSHOT 141
    • 16.6.2 REVENUE ANALYSIS 141
    • 16.6.3 PRODUCT PORTFOLIO 142
    • 16.6.4 RECENT DEVELOPMENT 142
  • 16.7 BIOMIND 143
    • 16.7.1 COMPANY SNAPSHOT 143
    • 16.7.2 PRODUCT PORTFOLIO 143
    • 16.7.3 RECENT DEVELOPMENT 143
  • 16.8 CEREBRAL DIAGNOSTIC 144
    • 16.8.1 COMPANY SNAPSHOT 144
    • 16.8.2 PRODUCT PORTFOLIO 144
    • 16.8.3 RECENT DEVELOPMENT 144
  • 16.9 DXCOVER LIMITED 145
    • 16.9.1 COMPANY SNAPSHOT 145
    • 16.9.2 PRODUCT PORTFOLIO 145
    • 16.9.3 RECENT DEVELOPMENT 145
  • 16.10 FONAR CORP. 146
    • 16.10.1 COMPANY SNAPSHOT 146
    • 16.10.2 REVENUE ANALYSIS 146
    • 16.10.3 PRODUCT PORTFOLIO 147
    • 16.10.4 RECENT DEVELOPMENT 147
  • 16.11 FUJIFILM CORPORATION 148
    • 16.11.1 COMPANY SNAPSHOT 148
    • 16.11.2 REVENUE ANALYSIS 148
    • 16.11.3 PRODUCT PORTFOLIO 149
    • 16.11.4 RECENT DEVELOPMENT 149
  • 16.12 GE HEALTHCARE. 150
    • 16.12.1 COMPANY SNAPSHOT 150
    • 16.12.2 REVENUE ANALYSIS 150
    • 16.12.3 PRODUCT PORTFOLIO 151
    • 16.12.4 RECENT DEVELOPMENT 151
  • 16.13 HITACHI, LTD. 152
    • 16.13.1 COMPANY SNAPSHOT 152
    • 16.13.2 REVENUE ANALYSIS 152
    • 16.13.3 PRODUCT PORTFOLIO 153
    • 16.13.4 RECENT DEVELOPMENT 153
  • 16.14 MINFOUND MEDICAL SYSTEMS CO., 154
    • 16.14.1 COMPANY SNAPSHOT 154
    • 16.14.2 PRODUCT PORTFOLIO 154
    • 16.14.3 RECENT DEVELOPMENT 154
  • 16.15 NANTOMICS. 155
    • 16.15.1 COMPANY SNAPSHOT 155
    • 16.15.2 PRODUCT PORTFOLIO 155
    • 16.15.3 RECENT DEVELOPMENT 155
  • 16.16 NEUSOFT CORPORATION 156
    • 16.16.1 COMPANY SNAPSHOT 156
    • 16.16.2 REVENUE ANALYSIS 156
    • 16.16.3 PRODUCT PORTFOLIO 157
    • 16.16.4 RECENT DEVELOPMENT 157
  • 16.17 SEQUOIA HEALTHCARE. 158
    • 16.17.1 COMPANY SNAPSHOT 158
    • 16.17.2 PRODUCT PORTFOLIO 158
    • 16.17.3 RECENT DEVELOPMENT 158
  • 16.18 STERNMED GMBH 159
    • 16.18.1 COMPANY SNAPSHOT 159
    • 16.18.2 PRODUCT PORTFOLIO 159
    • 16.18.3 RECENT DEVELOPMENT 159
  • 16.19 THERMO FISHER SCIENTIFIC INC. 160
    • 16.19.1 COMPANY SNAPSHOT 160
    • 16.19.2 REVENUE ANALYSIS 160
    • 16.19.3 PRODUCT PORTFOLIO 161
    • 16.19.4 RECENT DEVELOPMENT 161
  • 16.20 TIME MEDICAL HOLDING. 162
    • 16.20.1 COMPANY SNAPSHOT 162
    • 16.20.2 PRODUCT PORTFOLIO 162
    • 16.20.3 RECENT DEVELOPMENTS 162

17 QUESTIONNAIRE 163

18 RELATED REPORTS 166